Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas.

abstract：:A major side effect of cisplatin treatment is peripheral neuropathy. In the past few years we have provided evidence that the ACTH4-9 analogue ORG 2766 provides protection against this neuropathy in rats and man. In this study we investigated the development of a cisplatin-induced neuropathy and the protective and the...

journal_title：Cancer chemotherapy and pharmacology

authors： Hamers FP,Pette C,Bravenboer B,Vecht CJ,Neijt JP,Gispen WH

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Erlotinib (Tarceva®), a potent small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been evaluated to treat infants and children with primary brain tumors. The pharmacokinetics of erlotinib and its primary metabolite OSI-420 were characterized and exposure-safety associations we...

journal_title：Cancer chemotherapy and pharmacology

authors： Reddick SJ,Campagne O,Huang J,Onar-Thomas A,Broniscer A,Gajjar A,Stewart CF

更新日期：2019-10-01 00:00:00

abstract：:Larotaxel (XRP9881, RPR109881), a novel semi-synthetic taxoid that shares a mode of action with the taxanes docetaxel and paclitaxel, was active in preclinical studies against a broad spectrum of tumour cells and tumour models refractory/resistant to taxanes, and have demonstrated clinical activity in taxane pre-treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamamoto N,Boku N,Minami H

更新日期：2009-12-01 00:00:00

abstract：BACKGROUND:The pharmacokinetics and tissue distribution of photofrin II (PF) and its efficacy in sonodynamic therapy were studied in rats bearing AH130 solid tumors. MATERIALS AND METHODS:In order to find the optimum timing of the ultrasound exposure after administration of PF, the PF concentrations in plasma, skin, m...

journal_title：Cancer chemotherapy and pharmacology

authors： Yumita N,Umemura S

更新日期：2003-02-01 00:00:00

abstract：:The purpose of this trial was to minimize local inflammation caused by intravesical instillation of antitumor agents, especially Adriamycin, in the treatment of bladder tumor. Tranexamic acid was chosen as the solvent vehicle for Adriamycin and IV bolus injection of an antiallergic drug, Stronger neo-minophagen C, was...

journal_title：Cancer chemotherapy and pharmacology

authors： Ohi Y,Okamoto K,Kawabata T,Hanafusa A,Fai CY,Kakinoki T,Kawahara M,Asechi S,Sakamoto N,Nagata S

更新日期：1983-01-01 00:00:00

abstract：:Physicochemical properties of two types of adriamycin preparation, suspensions and emulsions prepared for i.a. chemotherapy of hepatocellular carcinoma, were investigated. A suspension was prepared by dispersing adriamycin directly into the lipid contrast medium, Lipiodol, whereas an emulsion was obtained by emulsifyi...

journal_title：Cancer chemotherapy and pharmacology

authors： Katagiri Y,Mabuchi K,Itakura T,Naora K,Iwamoto K,Nozu Y,Hirai S,Ikeda N,Kawai T

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:The plasma and cerebrospinal fluid (CSF) pharmacokinetics of the camptothecin analogs, 9-aminocamptothecin (9-AC) and irinotecan, were studied in a nonhuman primate model to determine their CSF penetration. METHODS:9-AC, 0.2 mg/kg (4 mg/m2) or 0.5 mg/kg (10 mg/m2), was infused intravenously over 15 min and iri...

journal_title：Cancer chemotherapy and pharmacology

authors： Blaney SM,Takimoto C,Murry DJ,Kuttesch N,McCully C,Cole DE,Godwin K,Balis FM

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:We have previously reported that intra-arterial chemotherapy prolongs the survival of patients with advanced HCC (aHCC); however, whether the response to intra-arterial chemotherapy depends on the etiology of underlying liver cirrhosis (LC) is still unknown. AIM:The aim of this study was to assess any influenc...

journal_title：Cancer chemotherapy and pharmacology

authors： Kanayama M,Nagai H,Sumino Y

更新日期：2009-06-01 00:00:00

abstract：PURPOSE:Midostaurin (PKC412) is a multitargeted tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 receptor (FLT3), c-KIT, and other receptors. Midostaurin is active in patients with acute myeloid leukemia and systemic mastocytosis. Although no substantive risk for cardiac abnormalities has been observed with mido...

journal_title：Cancer chemotherapy and pharmacology

authors： del Corral A,Dutreix C,Huntsman-Labed A,Lorenzo S,Morganroth J,Harrell R,Wang Y

更新日期：2012-05-01 00:00:00

abstract：PURPOSE:It remains challenging to identify patients at risk of anthracycline-induced cardiotoxicity. To better understand the different risk-stratifying approaches, we evaluated (123)I-metaiodobenzylguanidine ((123)I-mIBG) scintigraphy and its interrelationship with conventional echocardiography, 2D strain imaging and ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bulten BF,Verberne HJ,Bellersen L,Oyen WJ,Sabaté-Llobera A,Mavinkurve-Groothuis AM,Kapusta L,van Laarhoven HW,de Geus-Oei LF

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:To assess the clinical activity and toxicity of a combination chemotherapy regimen of S-1 and cisplatin in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in a retrospective study. METHODS:A total of 49 patients were treated in an outpatient setting with S-1 80 mg/m(2) o...

journal_title：Cancer chemotherapy and pharmacology

authors： Kim HS,Kim HR,Kim GM,Kim HS,Koh YW,Kim SH,Choi EC,Hong YK,Sung JH,Kim SM,Kim JH,Cho BC

更新日期：2012-10-01 00:00:00

abstract：:A sensitive solid-phase-extraction and high-performance liquid chromatography (HPLC) method has been developed to investigate the pharmacokinetics and metabolism of the hypoxic-cell cytotoxic agent tirapazamine (1,2,4-benzotriazine-3-amine 1,4-di-N-oxide; WIN 59075, SR 4233), currently in phase I/II studies in the Uni...

journal_title：Cancer chemotherapy and pharmacology

authors： Robin H Jr,Senan S,Workman P,Graham MA

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:To determine toxicities, maximally tolerated dose (MTD), pharmacokinetic profile, and potential antitumor activity of MTA, a novel antifolate compound which inhibits the enzymes thymidylate synthase (TS), glycinamide ribonucleotide formyltransferase (GARFT), and dihydrofolate reductase (DHFR). METHODS:Patients...

journal_title：Cancer chemotherapy and pharmacology

authors： Rinaldi DA,Kuhn JG,Burris HA,Dorr FA,Rodriguez G,Eckhardt SG,Jones S,Woodworth JR,Baker S,Langley C,Mascorro D,Abrahams T,Von Hoff DD

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:For the development of a safe and effective dual inhibitor of anticancer drug efflux transporters P-glycoprotein and multidrug resistance protein 1 (MRP1) to conquer multidrug resistance, we investigated the effects of dietary phytochemicals on the functions of P-glycoprotein and MRP1. METHODS:The effects of d...

journal_title：Cancer chemotherapy and pharmacology

authors： Nabekura T,Yamaki T,Ueno K,Kitagawa S

更新日期：2008-10-01 00:00:00

abstract：PURPOSE:In vitro and in vivo preclinical models have demonstrated synergistic activity when topoisomerase I and II inhibitors are administered sequentially. Topoisomerase I inhibitors increase topoisomerase II levels and increase cell kill induced by topoisomerase II poisons. We evaluated this hypothesis in a cohort of...

journal_title：Cancer chemotherapy and pharmacology

authors： Dowlati A,Levitan N,Gordon NH,Hoppel CL,Gosky DM,Remick SC,Ingalls ST,Berger SJ,Berger NA

更新日期：2001-01-01 00:00:00

abstract：PURPOSE:Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme important in DNA repair. PARP-1 activation at points of DNA strand break results in poly(ADP-ribose) polymer formation, opening the DNA structure, and allowing access of other repair enzymes. CEP-9722 inhibits PARP-1 and PARP-2 and is designed to potent...

journal_title：Cancer chemotherapy and pharmacology

authors： Plummer R,Stephens P,Aissat-Daudigny L,Cambois A,Moachon G,Brown PD,Campone M

更新日期：2014-08-01 00:00:00

abstract：PURPOSE:We conducted a phase II study of combination chemotherapy with nedaplatin (NP) and irinotecan (CPT) followed by gefitinib to determine the effects and toxicities in patients 70 years or older with unresectable non-small cell lung cancer (NSCLC). METHODS:Eligible patients were entered to receive 3 courses of 50...

journal_title：Cancer chemotherapy and pharmacology

authors： Oshita F,Yamada K,Saito H,Noda K

更新日期：2008-08-01 00:00:00

abstract：PURPOSE:Fenretinide is a synthetic retinoid with activity in prostate cancer and other cell lines. The aim of this study was to assess the efficacy and tolerability of fenretinide in chemotherapy-naïve men with hormone refractory prostate cancer. METHODS:Eligibility criteria included hormone refractory prostate cancer...

journal_title：Cancer chemotherapy and pharmacology

authors： Moore MM,Stockler M,Lim R,Mok TS,Millward M,Boyer MJ

更新日期：2010-10-01 00:00:00

abstract：PURPOSE:The blood-brain barrier discriminates the access of several molecules to the brain. This hampers the use of some drugs, as doxorubicin, potentially active for treatment of brain tumors. We explored the feasibility of active modification of the blood-brain barrier protection, by using morphine pretreatment, to a...

journal_title：Cancer chemotherapy and pharmacology

authors： Sardi I,la Marca G,Giovannini MG,Malvagia S,Guerrini R,Genitori L,Massimino M,Aricò M

更新日期：2011-06-01 00:00:00

abstract：:The technique of alkaline elution was employed to study the interactions of methylene dimethane sulphonate (MDMS) and formaldehyde (HCHO) with DNA from Yoshida lymphosarcoma cells treated with these agents. MDMS and HCHO produced a proteinase sensitive filter retention which indicated the presence of DNA-protein cross...

journal_title：Cancer chemotherapy and pharmacology

authors： O'Connor PM,Fox BW

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:Following a previously published pre-clinical validation, this phase I study evaluated the safety, maximum tolerated dose, anti-tumour activity and immune status of a gemcitabine-chloroquine combination as a first- or late-line treatment in patients with metastatic or unresectable pancreatic cancer. METHODS:In...

journal_title：Cancer chemotherapy and pharmacology

authors： Samaras P,Tusup M,Nguyen-Kim TDL,Seifert B,Bachmann H,von Moos R,Knuth A,Pascolo S

更新日期：2017-11-01 00:00:00

abstract：:Increasing the expression of human multidrug resistance (MDR) 1 gene in bone marrow cells to prevent or circumvent bone morrow toxicity from chemotherapy agent is a high priority of dose intensification protocols. In this study, we have used a tumor-bearing model to investigate the chemoprotection effect of MDR1 gene ...

journal_title：Cancer chemotherapy and pharmacology

authors： Guo CB,Li YC,Jin XQ

更新日期：2006-07-01 00:00:00

abstract：:S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters GJ,Noordhuis P,Van Kuilenburg AB,Schornagel JH,Gall H,Turner SL,Swart MS,Voorn D,Van Gennip AH,Wanders J,Holwerda U,Smid K,Giaccone G,Fumoleau P,Van Groeningen CJ

更新日期：2003-07-01 00:00:00

abstract：:Cell lines resistant to five antitumor alkylating agents (CDDP, PAM, 4-HC, HN2, and BCNU) were developed from five parental human tumor lines representative of solid tumors with a range of sensitivities to antitumor alkylating agents. The parental cell lines were SCC-25 squamous carcinoma of the head and neck, MCF-7 b...

journal_title：Cancer chemotherapy and pharmacology

authors： Frei E 3rd,Holden SA,Gonin R,Waxman DJ,Teicher BA

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:A group of 38 patients with advanced or metastatic NSCLC who had not rece...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsunoda T,Koizumi T,Hayasaka M,Hirai K,Koyama S,Takabayashi Y,Fujimoto K,Kubo K

更新日期：2004-08-01 00:00:00

abstract：PURPOSE:The purpose of this investigation was to synthesize a series of carbonate and carbamate derivatives of 4-demethylpenclomedine (DM-PEN), the major plasma non-toxic metabolite of penclomedine (PEN) seen in patients. DM-PEN has been observed to be an active antitumor agent in mouse human xenograft tumor models and...

journal_title：Cancer chemotherapy and pharmacology

authors： Morgan LR,Struck RF,Waud WR,LeBlanc B,Rodgers AH,Jursic BS

更新日期：2009-09-01 00:00:00

abstract：PURPOSE:Carboplatin is frequently dosed to achieve a desired area under the plasma concentration-time curve (AUC) by using the Calvert or Chatelut equations to estimate carboplatin clearance. Accurate determination of glomerular filtration rate (GFR) is necessary to correctly calculate carboplatin clearance using the C...

journal_title：Cancer chemotherapy and pharmacology

authors： Donahue A,McCune JS,Faucette S,Gillenwater HH,Kowalski RJ,Socinski MA,Lindley C

更新日期：2001-05-01 00:00:00

abstract：PURPOSE:While the target of many anticancer agents has been identified, the processes leading to killing of the cancer cells and the molecular basis of resistance to the drugs are not well understood. We used human gastrointestinal cancer cell lines and examined how anticancer agents induced cell killing and how the ch...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamamoto M,Maehara Y,Oda S,Ichiyoshi Y,Kusumoto T,Sugimachi K

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:Radiotherapy (RTx) has been considered as the treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). However, with only conventional fractionation (Cfx), response rates are relatively low. In this study, we report the results of hyperfractionation (Hfx) RTx with concurrent docetaxe...

journal_title：Cancer chemotherapy and pharmacology

authors： Katori H,Tsukuda M,Watai K

更新日期：2007-08-01 00:00:00

abstract：:Attenuation of the renal toxicity of cis-diamminedichloroplatinum (CDDP) is important in the use of this effective but cytotoxic anticancer agent. We have previously shown that the renal toxicity of CDDP can be efficiently reduced by the induction of metallothionein (MT) by preadministration of bismuth compounds in mi...

journal_title：Cancer chemotherapy and pharmacology

authors： Kondo Y,Himeno S,Satoh M,Naganuma A,Nishimura T,Imura N

更新日期：2004-01-01 00:00:00